Compare Nasdaq Inc (NDAQ) vs DENTSPLY SIRONA Inc (XRAY) Price & Performance

Nasdaq (NDAQ) trades at $92.37, up 0.48% with a bullish technical signal. The company shows strong fundamentals with Q2 2026 EPS beating expectations at $1.07 versus $0.984, and revenue growth from $7.4B in 2024 to $8.3B in 2025. Recent news highlights Nasdaq's AI-powered Calypso platform adoption by HSBC and Moderna joining the Nasdaq-100 Index, signaling business momentum. Valuation metrics include P/E of 26.93 and P/S of 6.07, with analyst consensus price target at $110.43.

NDAQ presents a favorable outlook with consistent earnings beats and strategic AI integration driving growth. Risks include market volatility sensitivity and debt levels, but strong institutional support and bullish analyst ratings suggest upside potential. The stock's current price offers a 19.6% discount to consensus target, making it attractive for growth-oriented investors seeking exposure to financial technology and market infrastructure.

DENTSPLY SIRONA (XRAY) trades at $8.69, down 1.76% on the day and near a 52-week low, reflecting ongoing operational challenges. The stock shows a bearish technical trend with weak moving averages, while fundamentals reveal declining revenue, negative net income margins, and elevated debt levels. Recent Q2 2026 earnings beat expectations but sales fell 4.1%, indicating persistent headwinds in dental markets.

The outlook remains cautious due to margin pressure and competitive threats, though analyst consensus suggests upside to a $13.40 price target. Key risks include execution of the turnaround plan, macroeconomic sensitivity, and high leverage. Investment appeal hinges on successful restructuring and recovery in core dental segments.